Hillgene provides full-service CDMO solutions for CAR-T, CAR-NK, and TCR-T therapies, supporting your journey from research to GMP manufacturing and beyond. As a specialized cell therapy CDMO, we offer expertise in CAR-T manufacturing, viral vector production, and regulatory support. Our agile team helps biotechs accelerate development with flexible, scalable, and compliant processes. Whether you're entering clinical trials or preparing for commercialization, our customized approach ensures speed, quality, and reliability at every stage. Partner with us to bring your next-generation therapies to life, faster and smarter.

Our Customers

Jiangsu Hillgene, headquartered in Suzhou with a 10,000㎡ GMP facility and R&D center, operates manufacturing sites in Shenzhen, Shanghai, Belgium, and the USA to strengthen its global presence. Hillgene has established specialized platforms for nucleic acid production, serum-free suspension culturing, closed-process development, ELISA kit and ELISA test-based QC testing for cellular therapies. These platforms have successfully supported the development of multiple CAR-T, TCR-T, and stem cell-based products. Hillgene is dedicated to accelerating cellular therapy advancements, bringing innovative treatments to patients faster.
Hillgene also provides comprehensive regulatory support, customized process development, and flexible manufacturing scales to suit projects from preclinical to commercial stages. Our expert team collaborates closely with clients to optimize timelines, reduce risks, and ensure compliance with global standards, making us a trusted CDMO partner in the cell and gene therapy space.
Successful IND Submissions
Prepared Cells for
Clinical Use
GMP Facility (m2)
Partnered GCP Sites